Stay updated on Pembrolizumab in Nasopharyngeal Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Nasopharyngeal Carcinoma Clinical Trial page.

Latest updates to the Pembrolizumab in Nasopharyngeal Carcinoma Clinical Trial page
- CheckyesterdayChange DetectedThe page now displays Revision: v3.3.4, replacing the previous Revision: v3.3.3. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page footer removes the HHS Vulnerability Disclosure link and adds a new revision note, Revision: v3.3.3 (replacing the previous v3.3.2).SummaryDifference0.1%

- Check51 days agoChange DetectedRevision updated from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check58 days agoChange DetectedRemoved 'Tainan City, Taiwan' from the locations and added 'Tainan, Taiwan'.SummaryDifference0.4%

- Check73 days agoChange DetectedThe updates are minor visual and layout adjustments to the study page with no substantive changes to core information such as eligibility criteria, outcomes, or locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check101 days agoChange DetectedUpdated version to v3.2.0 and added a government-operating-status notice; removed the prior v3.1.0 tag.SummaryDifference3%

Stay in the know with updates to Pembrolizumab in Nasopharyngeal Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Nasopharyngeal Carcinoma Clinical Trial page.